BidaskClub Upgrades BioScrip (BIOS) to Buy

BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a hold rating to a buy rating in a research report report published on Thursday.

A number of other brokerages have also issued reports on BIOS. SunTrust Banks set a $4.00 price objective on shares of BioScrip and gave the company a buy rating in a report on Thursday, December 21st. ValuEngine raised shares of BioScrip from a sell rating to a hold rating in a report on Thursday, November 30th. Finally, Zacks Investment Research lowered shares of BioScrip from a hold rating to a sell rating in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $3.63.

Shares of BioScrip (NASDAQ:BIOS) traded up $0.04 on Thursday, reaching $3.00. 423,300 shares of the company’s stock were exchanged, compared to its average volume of 574,775. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91. BioScrip has a twelve month low of $1.21 and a twelve month high of $3.39. The stock has a market cap of $382.55, a price-to-earnings ratio of -4.41 and a beta of 0.27.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The business had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same period in the prior year, the business posted ($0.12) earnings per share. BioScrip’s quarterly revenue was down 11.5% on a year-over-year basis. equities research analysts expect that BioScrip will post -0.63 EPS for the current year.

In other BioScrip news, CEO Daniel E. Greenleaf bought 15,000 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average cost of $2.03 per share, with a total value of $30,450.00. Following the completion of the acquisition, the chief executive officer now owns 31,000 shares in the company, valued at approximately $62,930. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of BioScrip in the third quarter valued at $114,000. Captrust Financial Advisors purchased a new position in BioScrip during the second quarter worth $123,000. Voya Investment Management LLC boosted its stake in BioScrip by 41.4% during the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after buying an additional 14,867 shares during the period. Highbridge Capital Management LLC purchased a new position in BioScrip during the third quarter worth $153,000. Finally, Skylands Capital LLC purchased a new position in BioScrip during the third quarter worth $272,000. 84.63% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

What are top analysts saying about BioScrip? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioScrip and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit